表紙
市場調査レポート

ポックスウイルス感染症:パイプライン製品の分析

Poxvirus Infections - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 302491
出版日 ページ情報 英文 39 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
ポックスウイルス感染症:パイプライン製品の分析 Poxvirus Infections - Pipeline Review, H1 2016
出版日: 2016年03月30日 ページ情報: 英文 39 Pages
概要

ポックスウイルス感染症はポックスウイルスにより発症する一連の感染症のことを指します。主な症状として、皮疹や高熱、発疹、筋肉痛、頭痛、体の痛み、嘔吐などが挙げられています。主な治療法には、抗ウイルス剤などがあります。

当レポートでは、世界各国でのポックスウイルス感染症治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

ポックスウイルス感染症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

ポックスウイルス感染症:企業で開発中の治療薬

ポックスウイルス感染症:大学/機関で研究中の治療薬

ポックスウイルス感染症:パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

ポックスウイルス感染症:企業で開発中の製品

ポックスウイルス感染症:大学/機関で研究中の製品

ポックスウイルス感染症の治療薬開発に従事している企業

  • China Biologic Products, Inc.
  • SIGA Technologies, Inc.
  • Symphogen A/S
  • 武田薬品工業

ポックスウイルス感染症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • 4-ThioIDU
  • ポックスウイルス感染症のための抗体
  • 感染症のためのモノクローナル抗体
  • ウイルス感染時のDNA合成を阻止するための小分子
  • ヘルペス・ポックスウイルス感染時のウイルス性DNAポリメラーゼを阻害するための小分子
  • Sym-002
  • tecovirimat
  • varicella hyperimmune globulins

ポックスウイルス感染症:最近のパイプライン動向

ポックスウイルス感染症:休止中のプロジェクト

ポックスウイルス感染症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7780IDB

Summary

Global Markets Direct's, 'Poxvirus Infections - Pipeline Review, H1 2016', provides an overview of the Poxvirus Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Poxvirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Poxvirus Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Poxvirus Infections
  • The report reviews pipeline therapeutics for Poxvirus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Poxvirus Infections therapeutics and enlists all their major and minor projects
  • The report assesses Poxvirus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Poxvirus Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Poxvirus Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Poxvirus Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Poxvirus Infections Overview
  • Therapeutics Development
    • Pipeline Products for Poxvirus Infections - Overview
    • Pipeline Products for Poxvirus Infections - Comparative Analysis
  • Poxvirus Infections - Therapeutics under Development by Companies
  • Poxvirus Infections - Therapeutics under Investigation by Universities/Institutes
  • Poxvirus Infections - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Poxvirus Infections - Products under Development by Companies
  • Poxvirus Infections - Products under Investigation by Universities/Institutes
  • Poxvirus Infections - Companies Involved in Therapeutics Development
    • China Biologic Products, Inc.
    • SIGA Technologies, Inc.
  • Poxvirus Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antibody for Poxvirus Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Infectious Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit DNA Synthesis for Poxvirus and Herpes Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tecovirimat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • varicella hyperimmune globulins - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Poxvirus Infections - Recent Pipeline Updates
  • Poxvirus Infections - Dormant Projects
  • Poxvirus Infections - Product Development Milestones
    • Featured News & Press Releases
      • Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA's Tecovirimat Antiviral
      • Mar 12, 2013: Siga Delivers First Courses Of Arestvyr To US Strategic National Stockpile Under BARDA Contract
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Poxvirus Infections, H1 2016
  • Number of Products under Development for Poxvirus Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Poxvirus Infections - Pipeline by China Biologic Products, Inc., H1 2016
  • Poxvirus Infections - Pipeline by SIGA Technologies, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Poxvirus Infections Therapeutics - Recent Pipeline Updates, H1 2016
  • Poxvirus Infections - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Poxvirus Infections, H1 2016
  • Number of Products under Development for Poxvirus Infections - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top